127 related articles for article (PubMed ID: 36036092)
1. An Opioid Hiding in Plain Sight: Loperamide-Induced False-Positive Fentanyl and Buprenorphine Immunoassay Results.
Geno KA; Badea A; Lynch KL; Jannetto P; Hubbard JA; Nerenz RD; Cervinski MA
J Appl Lab Med; 2022 Oct; 7(6):1318-1328. PubMed ID: 36036092
[TBL] [Abstract][Full Text] [Related]
2. Effect of tramadol use on three point-of-care and one instrument-based immunoassays for urine buprenorphine.
Shaikh S; Hull MJ; Bishop KA; Griggs DA; Long WH; Nixon AL; Flood JG
J Anal Toxicol; 2008 Jun; 32(5):339-43. PubMed ID: 18544218
[TBL] [Abstract][Full Text] [Related]
3. False-positive buprenorphine by CEDIA in patients prescribed amisulpride or sulpiride.
Birch MA; Couchman L; Pietromartire S; Karna T; Paton C; McAllister R; Marsh A; Flanagan RJ
J Anal Toxicol; 2013 May; 37(4):233-6. PubMed ID: 23471956
[TBL] [Abstract][Full Text] [Related]
4. Buprenorphine detection in urine using liquid chromatography-high-resolution mass spectrometry: comparison with cloned enzyme donor immunoassay (ThermoFisher) and homogeneous enzyme immunoassay (immunalysis).
Belsey SL; Couchman L; Flanagan RJ
J Anal Toxicol; 2014 Sep; 38(7):438-43. PubMed ID: 24925983
[TBL] [Abstract][Full Text] [Related]
5. Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: pharmacokinetics and pharmacodynamics in Sprague-Dawley rats.
Elkiweri IA; Zhang YL; Christians U; Ng KY; Tissot van Patot MC; Henthorn TK
Anesth Analg; 2009 Jan; 108(1):149-59. PubMed ID: 19095843
[TBL] [Abstract][Full Text] [Related]
6. Correction to: An Opioid Hiding in Plain Sight: Loperamide-Induced False-Positive Fentanyl and Buprenorphine Immunoassay Results.
J Appl Lab Med; 2024 May; 9(3):658. PubMed ID: 37935621
[No Abstract] [Full Text] [Related]
7. A Novel Enzyme Immunoassay for the Detection of Buprenorphine, Norbuprenorphine and Their Glucuronides in Urine.
Schubert B; Pitterl F; Saxl B; Pavlic M
J Anal Toxicol; 2019 Jun; 43(5):364-368. PubMed ID: 30753557
[TBL] [Abstract][Full Text] [Related]
8. Improved buprenorphine immunoassay performance after urine treatment with β-glucuronidase.
Snyder ML; Darragh A; Flood JG; Jones J; Ropar K; Jarolim P; Melanson SE
J Anal Toxicol; 2014; 38(6):375-9. PubMed ID: 24802159
[TBL] [Abstract][Full Text] [Related]
9. Commonly used fluoroquinolones cross-react with urine drug screens for opiates, buprenorphine, and amphetamines.
Colby JM; Patel PC; Fu DY; Rutherford NJ
Clin Biochem; 2019 Jun; 68():50-54. PubMed ID: 30991036
[TBL] [Abstract][Full Text] [Related]
10. Comparison of several immunoassays used in drugs of abuse screening: Assessment against gold standard methods and calculation of measurement uncertainty.
Mina A
J Pharmacol Toxicol Methods; 2020; 101():106649. PubMed ID: 31730939
[TBL] [Abstract][Full Text] [Related]
11. A new highly specific buprenorphine immunoassay for monitoring buprenorphine compliance and abuse.
Melanson SE; Snyder ML; Jarolim P; Flood JG
J Anal Toxicol; 2012 Apr; 36(3):201-6. PubMed ID: 22417836
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the performance of the Roche FEN2 fentanyl immunoassay and its clinical implementation: The role of LDT-based mass spectrometry testing.
Menlyadiev M; Suhandynata RT; Lund K; Kelner MJ; Fitzgerald RL
J Mass Spectrom Adv Clin Lab; 2023 Apr; 28():105-113. PubMed ID: 37025609
[TBL] [Abstract][Full Text] [Related]
13. Do all screening immunoassay positive buprenorphine samples need to be confirmed?
Saleem M; Martin H; Tolya A; Coates P
Ann Clin Biochem; 2017 Nov; 54(6):707-711. PubMed ID: 28121168
[TBL] [Abstract][Full Text] [Related]
14. Cross-reactivity of acetylfentanyl and risperidone with a fentanyl immunoassay.
Wang BT; Colby JM; Wu AH; Lynch KL
J Anal Toxicol; 2014; 38(9):672-5. PubMed ID: 25248490
[TBL] [Abstract][Full Text] [Related]
15. Consumption of the Sugar Substitute Stevia Leads to Cross-Reactivity of CEDIA® Buprenorphine II Immunoassay.
Plattner S; Pavlic M; Pitterl F; Schubert B
J Anal Toxicol; 2021 Nov; 45(9):1052-1057. PubMed ID: 33104778
[TBL] [Abstract][Full Text] [Related]
16. Detectability of fentanyl and designer fentanyls in urine by 3 commercial fentanyl immunoassays.
Helander A; Stojanovic K; Villén T; Beck O
Drug Test Anal; 2018 Mar; ():. PubMed ID: 29529707
[TBL] [Abstract][Full Text] [Related]
17. False-positive ethyl glucuronide immunoassay screening associated with chloral hydrate medication as confirmed by LC-MS/MS and self-medication.
Arndt T; Gierten B; Güssregen B; Werle A; Grüner J
Forensic Sci Int; 2009 Jan; 184(1-3):e27-9. PubMed ID: 19084359
[TBL] [Abstract][Full Text] [Related]
18. Long-term Buprenorphine Treatment for Loperamide Use Disorder: A Case Series.
Brar JK; Broyan VR; Allgaier JT; Nye L; Saxon AJ
J Addict Med; 2020 Dec; 14(6):e378-e381. PubMed ID: 32530885
[TBL] [Abstract][Full Text] [Related]
19. Comparison between drug screening by immunoassay and ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry in post-mortem urine.
Sundström M; Pelander A; Ojanperä I
Drug Test Anal; 2015 May; 7(5):420-7. PubMed ID: 24953563
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of buprenorphine CEDIA assay versus GC-MS and ELISA using urine samples from patients in substitution treatment.
Böttcher M; Beck O
J Anal Toxicol; 2005; 29(8):769-76. PubMed ID: 16356333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
